| Nov 14 |
Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutions
|
| Nov 13 |
Eledon Pharmaceuticals GAAP EPS of -$0.32 misses by $0.02
|
| Nov 12 |
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
|
| Nov 6 |
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
|
| Oct 29 |
Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart
|
| Oct 29 |
Eledon Pharmaceuticals prices 18.36M shares at $3.65 in underwritten offering
|
| Oct 29 |
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
|
| Oct 29 |
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
|
| Sep 11 |
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
|
| Jul 29 |
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
|
